Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Elamipretide
Clinical-stage mitochondria-targeting peptide binding cardiolipin. Not a typical consumer RUO product.
Tier Bmedium risk
02· Subject
MOTS-c
Mitochondrial-derived peptide studied in mouse models for metabolic homeostasis and insulin sensitivity.
Tier Chigh risk
01 · At a glance
| Decision factor | Elamipretide | MOTS-c | Epitalon |
|---|---|---|---|
| Primary fit | longevity & anti-aging research where you want a clear starting point | fat loss & metabolism and longevity & anti-aging comparisons | longevity & anti-aging and sleep & relaxation comparisons |
| Evidence | Tier B | Tier C | Tier C-D |
| Risk | medium | high | high |
| Experience level | advanced | advanced | advanced |
| Budget tier | premium | premium | mid |
| Administration route | subcutaneous, intravenous | subcutaneous | subcutaneous, intramuscular, intranasal |
02 · Use case & timing
| Decision factor | Elamipretide | MOTS-c | Epitalon |
|---|---|---|---|
| Goal fit | Longevity & Anti-Aging | Fat Loss & Metabolism, Longevity & Anti-Aging | Longevity & Anti-Aging, Sleep & Relaxation |
| What users compare it for | Mitochondrial function improvement in disease contexts (clinical-stage). | Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice. | Longevity/circadian claims; telomerase association not established as fact. |
| Onset timeline | Trial endpoints measured over months in disease-specific contexts. | Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days. | Often marketed as weeks-long courses; treat as hypothesis. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Elamipretide | MOTS-c | Epitalon |
|---|---|---|---|
| Adverse effects | Injection site reactions common in some trial summaries; long-term safety depends on indication. | FDA: no identified human exposure data; significant immunogenicity/characterization risks. | Sparse modern safety datasets; high uncertainty. |
| Contraindications | Clinical trial context; not consumer self-administration. | No human data. | No established data. |
| Interaction notes | Unknown in consumer context. | Unknown. | Unknown. |
| Regulatory status | Investigational | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution | FDA status unclear |
| WADA status | Not listed | Status unclear | Not listed |
04 · Age & monitoring
| Decision factor | Elamipretide | MOTS-c | Epitalon |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Not yet documented | Usually discussed in older-adult longevity and sleep-maintenance contexts, not younger performance use. |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Elamipretide | MOTS-c | Epitalon |
|---|---|---|---|
| Typical cycle cost | €371.52 | €33.02 | $59.98 |
| Estimated monthly cost | €371.52 | €33.02 | $79.97 |
| Cost confidence | High confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Elamipretide | MOTS-c | Epitalon |
|---|---|---|---|
| Tracked vendor listings | 1 listing | 3 listings | 3 listings |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | Product format varies by listing, so double-check route, concentration, and presentation. | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. |
| Stack-friendly? | Better as a standalone decision | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.